Jeffrey Alan Barnes, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphoma, Large B-Cell, Diffuse | 5 | 2024 | 1405 | 0.890 |
Why?
|
Lymphoma, B-Cell | 4 | 2019 | 940 | 0.730 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 11729 | 0.570 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 2 | 2016 | 164 | 0.440 |
Why?
|
Lymph Nodes | 2 | 2014 | 3469 | 0.400 |
Why?
|
Doxorubicin | 6 | 2024 | 2215 | 0.380 |
Why?
|
Antigens, CD19 | 2 | 2024 | 425 | 0.330 |
Why?
|
Vincristine | 4 | 2024 | 1036 | 0.320 |
Why?
|
Immunotherapy, Adoptive | 4 | 2024 | 1463 | 0.310 |
Why?
|
Hodgkin Disease | 3 | 2023 | 1378 | 0.290 |
Why?
|
Neurotoxicity Syndromes | 2 | 2023 | 300 | 0.290 |
Why?
|
Prednisone | 4 | 2024 | 1564 | 0.280 |
Why?
|
Cyclophosphamide | 4 | 2024 | 2218 | 0.260 |
Why?
|
Neutropenia | 2 | 2023 | 884 | 0.220 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 4 | 2013 | 694 | 0.210 |
Why?
|
Vinblastine | 2 | 2023 | 488 | 0.200 |
Why?
|
Lectins, C-Type | 1 | 2024 | 584 | 0.180 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 1640 | 0.180 |
Why?
|
Dacarbazine | 2 | 2023 | 559 | 0.180 |
Why?
|
Central Nervous System Neoplasms | 2 | 2023 | 916 | 0.170 |
Why?
|
Receptors, Immunologic | 1 | 2024 | 1411 | 0.150 |
Why?
|
Cysts | 1 | 2022 | 681 | 0.140 |
Why?
|
Disease-Free Survival | 3 | 2018 | 6813 | 0.130 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 2016 | 142 | 0.130 |
Why?
|
Hydroxamic Acids | 1 | 2018 | 481 | 0.130 |
Why?
|
Lymphatic Diseases | 2 | 2013 | 320 | 0.120 |
Why?
|
Lymphoma | 1 | 2023 | 1901 | 0.120 |
Why?
|
Jaw | 1 | 2013 | 93 | 0.110 |
Why?
|
Arabinonucleosides | 1 | 2013 | 34 | 0.110 |
Why?
|
Adenine Nucleotides | 1 | 2013 | 111 | 0.110 |
Why?
|
Sezary Syndrome | 1 | 2013 | 80 | 0.100 |
Why?
|
Hematuria | 1 | 2013 | 233 | 0.100 |
Why?
|
Lung Diseases | 1 | 2022 | 1909 | 0.100 |
Why?
|
Stem Cell Transplantation | 2 | 2018 | 1598 | 0.100 |
Why?
|
Fatal Outcome | 2 | 2013 | 1832 | 0.100 |
Why?
|
Confusion | 1 | 2013 | 278 | 0.100 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2015 | 549 | 0.090 |
Why?
|
Skin | 2 | 2016 | 4474 | 0.090 |
Why?
|
Hypercalcemia | 1 | 2013 | 423 | 0.090 |
Why?
|
Mediastinal Neoplasms | 1 | 2013 | 402 | 0.090 |
Why?
|
Radiography, Abdominal | 1 | 2013 | 533 | 0.090 |
Why?
|
Deltaretrovirus Antibodies | 1 | 2009 | 9 | 0.090 |
Why?
|
Diagnosis, Differential | 4 | 2016 | 12969 | 0.090 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2019 | 1373 | 0.090 |
Why?
|
Remission Induction | 2 | 2013 | 2394 | 0.090 |
Why?
|
Indoles | 1 | 2018 | 1833 | 0.090 |
Why?
|
Recurrence | 3 | 2018 | 8466 | 0.080 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1781 | 0.080 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2013 | 643 | 0.080 |
Why?
|
Male | 17 | 2024 | 360035 | 0.080 |
Why?
|
Aged | 13 | 2024 | 168840 | 0.080 |
Why?
|
Life Expectancy | 1 | 2015 | 1240 | 0.080 |
Why?
|
Administration, Oral | 2 | 2013 | 4010 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2012 | 4849 | 0.070 |
Why?
|
Urinary Bladder | 1 | 2013 | 1150 | 0.070 |
Why?
|
Bone Marrow | 2 | 2013 | 2907 | 0.070 |
Why?
|
Survival Analysis | 2 | 2019 | 10075 | 0.070 |
Why?
|
Suprachiasmatic Nucleus | 2 | 2004 | 140 | 0.070 |
Why?
|
Humans | 24 | 2024 | 760437 | 0.060 |
Why?
|
Middle Aged | 13 | 2024 | 220382 | 0.060 |
Why?
|
Sirolimus | 1 | 2012 | 1533 | 0.060 |
Why?
|
Fatigue | 1 | 2012 | 1550 | 0.060 |
Why?
|
Biological Clocks | 2 | 2004 | 316 | 0.060 |
Why?
|
Adult | 11 | 2024 | 220781 | 0.060 |
Why?
|
Cyclic GMP-Dependent Protein Kinases | 1 | 2004 | 28 | 0.060 |
Why?
|
Female | 15 | 2024 | 391875 | 0.060 |
Why?
|
Photoreceptor Cells, Invertebrate | 1 | 2003 | 39 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 20551 | 0.060 |
Why?
|
Methotrexate | 1 | 2010 | 1720 | 0.060 |
Why?
|
Treatment Outcome | 7 | 2024 | 64591 | 0.060 |
Why?
|
Aged, 80 and over | 4 | 2018 | 58859 | 0.050 |
Why?
|
Emigrants and Immigrants | 1 | 2009 | 543 | 0.050 |
Why?
|
Anemia | 1 | 2012 | 1508 | 0.050 |
Why?
|
Circadian Rhythm | 2 | 2004 | 2572 | 0.050 |
Why?
|
Bleomycin | 1 | 2023 | 494 | 0.050 |
Why?
|
Lymphoma, T-Cell | 1 | 2024 | 304 | 0.050 |
Why?
|
Pruritus | 2 | 2016 | 378 | 0.050 |
Why?
|
Transplantation, Homologous | 1 | 2009 | 4808 | 0.050 |
Why?
|
Models, Statistical | 1 | 2015 | 5078 | 0.040 |
Why?
|
Eye Proteins | 1 | 2003 | 633 | 0.040 |
Why?
|
Pain | 1 | 2013 | 5075 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 1008 | 0.030 |
Why?
|
Central Nervous System | 1 | 2023 | 1337 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2024 | 3590 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 2024 | 2202 | 0.030 |
Why?
|
Leg Injuries | 1 | 2016 | 179 | 0.030 |
Why?
|
Drosophila Proteins | 1 | 2003 | 1698 | 0.030 |
Why?
|
Mastocytosis | 1 | 2016 | 149 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2013 | 5815 | 0.030 |
Why?
|
Dermatitis, Exfoliative | 1 | 2013 | 27 | 0.030 |
Why?
|
Sarcoma, Kaposi | 1 | 2016 | 374 | 0.030 |
Why?
|
Piperidines | 1 | 2021 | 1656 | 0.030 |
Why?
|
HIV Infections | 1 | 2019 | 17328 | 0.030 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2013 | 97 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1942 | 0.030 |
Why?
|
Antibodies, Monoclonal | 2 | 2024 | 9176 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3822 | 0.020 |
Why?
|
Sulfonamides | 1 | 2021 | 1973 | 0.020 |
Why?
|
Markov Chains | 1 | 2015 | 965 | 0.020 |
Why?
|
Exanthema | 1 | 2016 | 504 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2009 | 5663 | 0.020 |
Why?
|
Oligonucleotides, Antisense | 2 | 2004 | 461 | 0.020 |
Why?
|
Pyrazoles | 1 | 2021 | 2007 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1896 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2013 | 11095 | 0.020 |
Why?
|
Biological Products | 1 | 2019 | 911 | 0.020 |
Why?
|
Young Adult | 4 | 2019 | 59068 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1549 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2024 | 12320 | 0.020 |
Why?
|
Neoplasm Staging | 2 | 2015 | 11096 | 0.020 |
Why?
|
Pyrimidines | 1 | 2021 | 3024 | 0.020 |
Why?
|
Causality | 1 | 2015 | 1243 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2024 | 80430 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2010 | 1379 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2501 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 16945 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2642 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1887 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2569 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2297 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10188 | 0.020 |
Why?
|
Dermatitis, Atopic | 1 | 2013 | 716 | 0.020 |
Why?
|
Population Surveillance | 1 | 2015 | 2603 | 0.010 |
Why?
|
Flavoproteins | 1 | 2003 | 40 | 0.010 |
Why?
|
Transcription Factors | 1 | 2003 | 12121 | 0.010 |
Why?
|
Cryptochromes | 1 | 2003 | 48 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2016 | 2462 | 0.010 |
Why?
|
Period Circadian Proteins | 1 | 2003 | 96 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4319 | 0.010 |
Why?
|
NIH 3T3 Cells | 1 | 2004 | 671 | 0.010 |
Why?
|
Rats, Inbred Lew | 1 | 2004 | 1155 | 0.010 |
Why?
|
Rats, Inbred Strains | 1 | 2003 | 2090 | 0.010 |
Why?
|
Boston | 1 | 2015 | 9326 | 0.010 |
Why?
|
Computer Simulation | 1 | 2015 | 6230 | 0.010 |
Why?
|
United States | 1 | 2009 | 72202 | 0.010 |
Why?
|
Electrophysiology | 1 | 2003 | 1263 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2015 | 12429 | 0.010 |
Why?
|
Comorbidity | 1 | 2015 | 10494 | 0.010 |
Why?
|
Mice | 2 | 2024 | 81402 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14661 | 0.010 |
Why?
|
RNA, Messenger | 2 | 2004 | 12785 | 0.010 |
Why?
|
Risk | 1 | 2010 | 9605 | 0.010 |
Why?
|
Animals | 3 | 2024 | 168253 | 0.010 |
Why?
|
Rats | 2 | 2004 | 23712 | 0.010 |
Why?
|
Prospective Studies | 1 | 2022 | 54339 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2015 | 20078 | 0.010 |
Why?
|
Incidence | 1 | 2015 | 21322 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 4567 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 41366 | 0.010 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2003 | 1248 | 0.010 |
Why?
|
Transfection | 1 | 2003 | 5776 | 0.010 |
Why?
|
RNA Interference | 1 | 2003 | 2832 | 0.010 |
Why?
|
Risk Assessment | 1 | 2015 | 23953 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2003 | 2870 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2003 | 3446 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2013 | 39078 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 13616 | 0.010 |
Why?
|
Cell Line | 1 | 2003 | 15598 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2003 | 5794 | 0.000 |
Why?
|
Neurons | 1 | 2003 | 9443 | 0.000 |
Why?
|
Time Factors | 1 | 2004 | 39947 | 0.000 |
Why?
|